Aardvark Therapeutics Inc宣布,公司将揭盲其候选药物Ard-101在HERO试验和开放标签扩展(OLE)试验中的数据,以进行全面评估。此举旨在基于这些关键临床数据,为Ard-101项目的未来发展路径做出决策。
Aardvark Therapeutics Inc宣布,公司将揭盲其候选药物Ard-101在HERO试验和开放标签扩展(OLE)试验中的数据,以进行全面评估。此举旨在基于这些关键临床数据,为Ard-101项目的未来发展路径做出决策。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.